Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxart Inc (NQ: VXRT )

0.8716 +0.0486 (+5.91%)
Streaming Delayed Price Updated: 3:38 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vaxart Inc

< Previous 1 2 3 4 5 6 7 8 Next >
Vaxart Stock Could Make Another Big Return in the Future
It might be tempting to dismiss VXRT stock now that other Covid-19 vaccines are available, but pill-based vaccines for diseases are appealing. 
Via InvestorPlace
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2021
Upgrades For Taiwan Semiconductor Manufacturing Co Ltd (NYSE: 
Via Benzinga
Will the Promise of Avoiding the Needle Pay Off for Vaxart?
VXRT stock just received a buy recommendation and a $13 price target from Jefferies, based on the promise of a oral vaccine instead of a needle. 
Via InvestorPlace
Exposures COVID-19
Why Vaxart Shares Are Trading Higher Today
Vaxart Inc (NASDAQ:VXRT) shares are trading higher by 30% ... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2021
Upgrades Zelman upgraded the previous rating for Armstrong World Industries Inc (NYSE: 
Via Benzinga
Is Now The Time To Buy Stock Or Options In Apple, PayPal, Square Or Vaxart?
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why I... 
Via Benzinga
VXRT Stock: Can Redditors Help Vaxart Power Higher?
Today, VXRT stock is climbing higher on an otherwise red day for the markets, as many speculate retail investors could be behind this rise. 
Via InvestorPlace
Vaxart Is Still Not Worth Anywhere Near Its Present Price
Vaxart is still not worth today's price. VXRT stock is worth no more than $6, especially if it's going to need another capital raise. 
Via InvestorPlace
Exposures COVID-19
Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today
The declines appear to be caused simply by volatility that's common with small biotech stocks. 
Via The Motley Fool
Exposures COVID-19
Is It Too Late to Buy Vaxart Stock?
The science looks fishy for this small-cap biotech. 
Via The Motley Fool
Exposures COVID-19
Meme Stocks Continue To Surge As Traders Move To Biotech
The meme stock crowd turned its attention to biotech and healthcare stocks, boosting some shares by as much as 10%. 
Via Talk Markets
VXRT Stock: Why Redditors Are Betting on a Big Squeeze With Vaxart Today
VXRT stock is on the move as the company received some very bullish coverage from an analyst initiating coverage today. 
Via InvestorPlace
64 Biggest Movers From Friday
Gainers Kanzhun Limited (NASDAQ: BZ) shares climbed 95.8% to close at $37.20 on Friday after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares gained... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Most Active Equity Options For Midday - Friday, June 11
Top tickers for midday: AMC, AAPL, TSLA, NIO, NVDA, AMZN, CLOV, SNAP, CLF, GME, PLTR, VXRT, AMD, MO, F, SENS, BAC, MSFT, BB, ET. 
Via Talk Markets
Nasdaq, S&P 500 Eye Weekly Wins as Bond Yields Retreat
The 10-year Treasury bond yield fell to a three-month low. 
Via Talk Markets
Topics Bonds Stocks
Exposures Debt Markets US Equities
46 Stocks Moving In Friday's Mid-Day Session
Gainers Kanzhun Limited (NASDAQ: BZ) shares surged 77.4% to $33.70 after the company priced its IPO at $19 per share. Novan, Inc. (NASDAQ: NOVN) shares jumped 73.3% to $15.67... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Novan (NASDAQ:NOVN) stock rose 71.04% to $15.46 during Friday's regular session. As of 12:30 EST, Novan's stock is trading at a volume of 109.3 million,... 
Via Benzinga
Why Vaxart Stock Is Skyrocketing Today
Investors are cheering an analyst's positive recommendation. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to... 
Via Benzinga
Why Shares of Vaxart Plummeted 38.6% in May
This isn't the first time its coronavirus vaccine pill has disappointed investors. 
Via The Motley Fool
Exposures COVID-19
Bet on a No-Needle Vaccine Strategy with Vaxart
Reimagining Covid-19 vaccines isn't an easy task, but Vaxart is prepared to innovate - and VXRT stock could move higher at any given moment. 
Via InvestorPlace
Exposures COVID-19
10 More Current & Former Penny Stocks With High Short Interest
High Short Interest Stocks Are Something Traders Are On The Hunt For & Here's Another 10 
Via Talk Markets
28 Stocks Moving in Tuesday's Pre-Market Session
Gainers Aytu Biopharma, Inc. (NASDAQ: AYTU) rose 37.8% to $7.40 in pre-market trading. Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) rose 23.5% to $3.89 in pre-market trading... 
Via Benzinga
5 High-Octane Growth Stocks With 54% to 94% Upside, According to Wall Street
If analysts are correct, this assortment of rapidly growing companies could deliver big-time returns over the next year. 
Via The Motley Fool
Topics Economy
Exposures Economy
These Vaccine Latecomers Could Still Win Big. Here's How
The key is standing out from the crowd. 
Via The Motley Fool
Topics Cannabis
Exposures COVID-19 Cannabis
Vaxart’s Compelling Story Will Take a Long Time to Play Out
As a company attempting to make oral vaccines, Vaxart has a compelling story. However VXRT stock looks to be many years away from paying off. 
Via InvestorPlace
Exposures COVID-19
With Fading Covid-19 Infections, Vaxart’s Relevance Is Waning
Prior to the vaccination rollout from Vaxart’s competitors, VXRT stock appeared a compelling alternative. That’s no longer the case. 
Via InvestorPlace
Exposures COVID-19
Speculators Should Consider Buying Vaxart Stock
Vaxart's vaccine pill could prove to be effective against the original Covid-19 virus and its new variants, sending VXRT stock sky-high. 
Via InvestorPlace
Exposures COVID-19
Vaxart Could Still Be a Viable Covid 19 Vaccine Play
VXRT stock needs to nail the next few studies of its Covid-19 vaccine candidate and prove its thesis to strengthen its bull case. 
Via InvestorPlace
Exposures COVID-19
Ocugen or Vaxart: Which Will Take Investors Further?
These two high-flying biotechs are vying for the same market. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.